Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
AGENUS INC issued 2,133,333 shares of common stock to Zynext Ventures USA LLC for $16.0 million ($7.50/share).
- Security
- common stock
- Shares
- 2,133,333 shares
- Purchaser
- Zynext Ventures USA LLC
- Consideration
- $16.0 million ($7.50/share)
Exact text from the filing
Agreement (the “SPA”), pursuant to which Zynext agreed to purchase 2,133,333 shares of the Company’s common stock (the “Shares”) for an aggregate purchase price of approximately $16.0 million, or $7.50 per share. On January 15, 2026, the transactions contemplated by the SPA closed. The foregoing description of the SPA does not purport to be complete and is qualified
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.95
AGENUS INC completed a disposition involving Zydus Pharmaceuticals (USA) Inc. (subsequently assigned to Zydilac Bio, LLC) for $75.0 million (closed 2026-01-15).
- Action
- disposition
- Counterparty
- Zydus Pharmaceuticals (USA) Inc. (subsequently assigned to Zydilac Bio, LLC)
- Consideration
- $75.0 million
- Closing
- 2026-01-15
Exact text from the filing
On January 15, 2026, the transactions contemplated by the Purchase Agreement closed. Pursuant to the Purchase Agreement, on January 15, 2026, Agenus received consideration of $75.0 million, less certain reimbursable expenses and other required closing payments. The disposition of the Purchased Assets constituted a significant business disposition for the purposes
View on SEC.gov